Erin Allman‑Updyke and Erin Welsh
speaker
988 appearances
1 recordings
1 series
first heard Aug 2026
last heard 4 Aug
Erin Allman‑Updyke and Erin Welsh’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Aug 2026 with 1.
Appearances
It's a statin.
It's a statin.
But because it's extracted from a plant, plants produce different levels of these things.
And so you have no idea how much you're getting.
And so it can be dangerous.
You could be on very low dose, non-existent dose versus high intensity or whatever.
And most brands in studies that have looked at this have no detectable levels of that actual compound, right?
There's no regulation on the composition of those particular supplements.
There's no regulation on how much of that compound, like you said, the yeast is actually going to produce when it's fermented.
So there's batch to batch variation.
There's brand to brand variation.
And at the end of the day, it's an unregulated statin.
It's unregulated.
Yeah.
And I don't want to make that sound like, oh, well, pharmaceutical companies are just the best thing ever.
No, no.
They're not.
And it's also not the case that our guidelines might not be subject to some degree of bias because, like you mentioned, of the conflicts of interest that exist within cardiology and within, like, I mean, all fields of medicine, realistically.
A good number of the authors and the people who were involved in the peer review process for the newest dyslipidemia guidelines in the U.S.
have financial conflicts of interest, not just with pharmaceutical companies, but with imaging companies, with genetic testing companies.
Showing 861–880 of 988 · page 44 of 50
← Previous
Next →